Status:
COMPLETED
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Lead Sponsor:
Lin Chen
Conditions:
Advanced Gastric Carcinoma
Immunotherapy
Eligibility:
All Genders
18-80 years
Brief Summary
To vertify the function of circulating exosomal lncRNA-GC1 on predicting and monitoring immunotherapeutic outcomes of GC
Detailed Description
The investigator's previous work identified circulating exosomal lncRNA-GC1 as a GC-specific tumor burden marker and this novel biomarker showed promising efficiency in monitoring disease progression ...
Eligibility Criteria
Inclusion
- Having signed informed consent
- Age≥ 18 years old
- Histologically confirmed gastric adenocarcinoma
- Unresectable recurrent or metastatic disease
- Measurable disease according to the RECIST criteria
- Life expectancy of ≥3 month
- No prior chemotherapy of the study more than 4 weeks
- Immunotherapy regimens were included in the treatment
Exclusion
- Other previous malignancy within 5 year
- Surgery (excluding diagnostic biopsy) within 4 weeks prior to study
- Pregnancy or lactation period
- Legal incapacity
Key Trial Info
Start Date :
November 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05334849
Start Date
November 1 2018
End Date
September 30 2022
Last Update
October 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853